Blockchain Registration Transaction Record

SS Innovations Submits FDA Response for SSi Mantra Robotic System

SS Innovations submits FDA response for SSi Mantra surgical robot, advancing toward U.S. market entry. Final data included; FDA review expected Q1 2027.

This development matters because it brings SS Innovations one step closer to entering the U.S. surgical robotics market, which is currently dominated by a few major players. The SSi Mantra system's potential FDA clearance could offer hospitals and surgeons a more affordable and accessible option for robotic-assisted surgery, ultimately benefiting patients through increased access to minimally invasive procedures. The successful submission of the FDA response and the anticipation of a review completion in early 2027 signals progress in regulatory approval, which could lead to commercialization and adoption in the U.S., impacting the competitive landscape and potentially reducing healthcare costs associated with robotic surgery.